Evidence map›Paper›PMID 39940052›Full record

ArticleEuropean journal of medical research2025

Unveiling the prognostic significance of RNA editing-related genes in colon cancer: evidence from bioinformatics and experiment.

Zhengcong Deng, Xueqin Jin, Bingxue Liu, Hongyan Zhen, Xiang Wang

Abstract read
In one paragraph

Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Zhengcong Deng *Hubei Third People's Hospital, Wuhan, 430033, Hubei, China.
Xueqin Jin *Hubei Third People's Hospital, Wuhan, 430033, Hubei, China.
Bingxue LiuMedical School, Jianghan University, Wuhan, 430056, Hubei, China.
Hongyan ZhenMedical School, Jianghan University, Wuhan, 430056, Hubei, China.
Xiang WangMedical School, Jianghan University, Wuhan, 430056, Hubei, China. wangxiang@jhun.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRNA editing is recognized as a crucial factor in cancer biology. Its potential application in predicting the prognosis of colon adenocarcinoma (COAD) remains unexplored.

methodsRNA editing data of COAD patients were downloaded from the Synapse database. LASSO regression was used to construct the risk model and verified by the receiver operating characteristic (ROC) curve. GO and KEGG enrichment analyses were performed to delineate the biological significance of the differentially expressed genes. Finally, differential analysis and immunohistochemistry were used to verify the expression of adenosine deaminase 1 (ADAR1).

resultsWe evaluated a total of 4079 RNA editing sites in 514 COAD patients from Synapse database. A prognostic signature was constructed based on five genes were significantly associated with the prognosis of COAD patients including GNL3L, NUP43, MAGT1, EMP2, and ARSD. Univariate and multivariate Cox regression analysis revealed that RNA editing-related genes (RERGs)-related signature was an independent risk factor for COAD. Moreover, Experimental evidence shows that ADAR1 is highly expressed in colon adenocarcinoma and silencing ADAR1 can inhibit cancer cell proliferation.

conclusionWe established a prognostic model based on five RERGs with strong predictive value. This model not only serves as a foundation for a novel prognostic tool but also facilitates the identification of potential drug candidates for treating COAD.

Indexed as

AdenocarcinomaAdenosine DeaminaseBiomarkers, TumorColonic NeoplasmsRNA EditingComputational BiologyFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedPrognosisRNA-Binding ProteinsADAR protein, humanAdenosine DeaminaseBiomarkers, TumorRNA-Binding ProteinsADAR1Colon adenocarcinomaPrognostic modelRNA editing

Identifiers

PMID39940052
PMCPMC11823094

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.